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Abstract 
Objectives: There remains a need to identify effective smoking cessation interventions in 
severely disadvantaged populations. This trial aimed to examine the effectiveness of an 
intervention (Call it Quits) developed to promote smoking cessation and delivered by 
community social service case-workers. 
Methods: Call it Quits was a pragmatic, parallel randomised trial of a case-worker delivered 
smoking cessation intervention conducted in a non-government community social service 
organisation in New South Wales (NSW), Australia. Adult smokers requiring financial 
assistance were randomly assigned to the five-session Call it Quits intervention or usual care 
control group. Of the 618 eligible individuals, 300 were randomised to the intervention 
group, of whom 187 (62%) consented and 318 were randomised to the control group, of 
whom 244 (77%) consented, resulting in 431 participants. 
The primary outcome measure was self-reported continuous abstinence up to 6-month 
follow-up with biochemical verification. Primary analysis was performed using all the 
available data from participants under the assumption the data is missing completely at 
random , followed by sensitivity analyses.  
Results: No statistically significant differences in the primary outcome were found (1.4% in 
the control group versus 1.0% in the intervention group, OR=0.77, p=0.828). 
Conclusions: A multi-component smoking cessation intervention delivering motivational 
interviewing-based counselling and free NRT by a trained case-worker within a community 
social service setting was not effective at achieving abstinence in a highly disadvantaged 
sample of smokers but increased attempts to stop and led to a reduction in number of 
cigarettes smoked daily. 
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Trial Registration: This study was registered with Australian New Zealand Clinical Trials 
Registry (ISRCTN85202510). 
Keywords 
Smoking cessation; disadvantaged population; vulnerable groups 
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Highlights 
 First smoking cessation trial in a community based social service setting 
 Participants were socioeconomically disadvantaged smokers with comorbidity 
 Case-worker delivered intervention were not effective at aiding abstinence  
 Important gains were made in reductions in cigarettes smoked and quit attempts. 
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Introduction 
In high-income countries, tobacco smoking rates are highest amongst people with mental 
illness and substance use disorders, the long term unemployed and homeless populations, and 
Indigenous peoples.
1
 Rates of tobacco-related diseases such as cardiovascular disease, cancer 
and chronic respiratory diseases are subsequently much higher in these groups.
2
 
Smokers from these disadvantaged, low socioeconomic groups find it harder to quit than 
more socioeconomically advantaged smokers.
1,3
 Existing evidence for the effectiveness of 
smoking cessation interventions for disadvantaged groups is inconsistent and inconclusive. 
Two systematic reviews of smoking cessation interventions for six disadvantaged groups 
known to have high smoking rates in high-income countries suggest that multicomponent 
interventions incorporating behavioural counselling either face-to-face or via telephone, 
motivational interviewing, and NRT hold the greatest promise of successfully achieving 
abstinence amongst some disadvantaged groups but not all.
4,5
  
Delivering comprehensive smoking cessation interventions to smokers who experience 
disadvantage is challenging as these smokers are often hard-to-reach and as a result sample 
sizes are small.
4-6
 In high-income countries including the UK, US and Australia, community 
social service organisations (CSSO) provide support to the most socially disadvantaged 
groups
7
 with high smoking rates.
8
 Small pilot smoking cessation trials suggest that the CSSO 
setting might be acceptable and feasible,
8,9
 however, the effectiveness of this approach has 
not been evaluated in an adequately powered trial. 
Objectives 
The primary aim of this study was to examine the effectiveness of a CSSO case-worker 
delivered intervention (Call it Quits) for a diverse population of severely disadvantaged 
smokers on verified continuous abstinence at six month follow-up.  
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Methods 
Study design and setting: Call it Quits was a parallel randomised trial of a case-worker 
delivered smoking cessation intervention.
10
 The study was conducted in a large Community 
Care Centre, managed by a national non-government organisation located in New South 
Wales (NSW) Australia providing counselling, emergency housing and financial aid.   
Participants: Participants were adult clients of the Community Care Centre, who self-
reported smoking daily or occasionally, with sufficient English language to give informed 
consent. Clients who presented to the centre in an inebriated or agitated state or were too  
distressed (distress related to factors contributing to accessing emergency relief) to participate 
were excluded.  
As clients arrived at the Centre, eligibility was assessed by a research assistant who obtained 
written consent. First, the research assistant asked participants to complete a general health 
survey on a touchscreen laptop computer. Second, participants who reported smoking 
tobacco daily or occasionally were asked by the research assistant to participate in a study 
where they may or may not receive a smoking cessation program requiring them to return to 
the Centre. Participant sociodemographic and smoking characteristics were collected during 
the computer-administered general health survey (Supplementary File 1). 
Randomisation and masking: A computer generated randomisation schedule which was 
embedded into the computer survey software allocated trial participants in a 1:1 ratio to 
intervention or control group. The randomisation schedule was developed by an independent 
computer programmer, incorporated into the Digivey survey software,
11
 and tested prior to 
the trial commencing. At enrolment, the sequence was concealed from the research assistant 
who gained consent into the trial and conducted follow-up assessments. Participants were 
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made aware of their group following allocation with a paper print-out after they completed 
the computer survey. 
Interventions: All participants received on-screen advice to quit smoking, the state Quitline 
telephone number, and a “gift bag” with Call it Quits branded gifts. All participants were 
asked to return to the centre at 1 month and 6 month follow-up for data collection. No further 
intervention was offered to control group participants. 
The smoking cessation intervention which was drawn from existing evidence, the PRIME 
theory of motivation,
12
 and the taxonomy of Behaviour Change Techniques (BCTs),
13
 used 
brief advice and motivational interviewing techniques to encourage setting a quit date and 
maximise use of NRT,
14
 and provide social support.
15
 Free NRT was offered to all 
participants in the intervention group. Combination use of fast acting and sustained release 
NRT was encouraged based on evidence of increased effectiveness compared with single 
NRT type use.
14
 The schedule of counselling sessions for intervention delivery included three 
face-to-face sessions and two telephone sessions. The counselling sessions were delivered by 
trained volunteer case-workers to mirror usual counselling practice at the Centre. and 
followed a written intervention manual (Supplementary File 2) which incorporated 46 BCTs. 
The emphasis was on setting a quit date, encouraging use of NRT, managing withdrawal 
symptoms and urges to smoke, enhancing self-efficacy, social support and prevention of 
relapse. 
Evidence-based strategies were employed to minimise attrition
6
 including collection of 
comprehensive contact information for the participant and a significant other, flexible 
scheduling of follow-up assessments with reminder text messages and calls, and project 
branded gift bags. All participants received up to $120AUD grocery voucher for completion 
of the surveys. 
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Outcomes: The primary outcome was CO verified self-reported continuous abstinence at six 
months follow-up, with abstinence defined according to the Russell Standard (modified – 
regarding treatment of missing cases, see below).
16
 Prior to un-blinding and data analysis, this 
was changed from the original protocol outcomes of 24-hour CO verified self-reported 
abstinence and 7-day point prevalence self-reported abstinence based on recommendations 
that six months continuous abstinence is the more relevant outcome for evaluating longer-
term cessation and health impacts.
17
 At the same time the 12 month follow-up was abandoned 
due to concerns regarding attrition and resourcing. To be classified as abstinent, participants 
had to report that they had smoked fewer than five cigarettes in each of the previous six 
months, from two weeks after the baseline (grace period) at the six-month follow-up visit and 
that they had not smoked any cigarettes in the week before the follow-up visit. As explained 
in the protocol paper,
10
 although cotinine is the recommended gold standard measure for the 
verification of smoking status, it was impractical and invasive in this study and abstinence 
was verified by the concentration of exhaled CO of less than 10 ppm.
18
 All participants were 
asked to return to the centre to provide a CO reading, regardless of whether they reported 
abstinence. 
Secondary outcomes were self-reported continuous abstinence at 1 month follow-up, and at 
both 1 month and 6 month follow-up self-reported and verified 7 day point prevalence 
abstinence, cigarettes smoked per day, and number of serious attempts to quit in the last 
month.  
To assess adherence to the intervention, participation in face-to-face and telephone sessions 
was recorded by counselling case-workers and participants were asked about use of NRT. 
Audio-recordings of 67 counselling sessions were coded for manual-specified BCT delivery. 
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Statistical analysis: The statistical analysis plan was approved by all investigators before un-
blinding (available upon request). Primary analysis was performed using all the available data 
from participants under the assumption the data is missing completely at random , followed 
by a range of sensitivity analyses to investigate the impact of departures from the missing 
data assumptions.
19
 As recommended by the CONSORT statement, statistical analyses were 
conducted on all primary and secondary outcomes, and not on baseline data. 
The primary outcome measure - continuous abstinence from baseline (with a two week grace 
period) – requires that participants be abstinent at both one month and six month follow-up.16 
Thus participants who are missing outcome data at six months, but are followed up at one 
month and are not abstainers at this time are by definition not continuous abstainers at six 
months and were classified as such in the analyses. All other participants with missing 
outcome data were excluded from the primary analysis.  
The primary analysis of CO verified continued abstinence from baseline involved a logistic 
regression model of all available observations (according to the definition above). SAS 9.4 
and Stata 13 were used for all analyses, and statistical significance was defined a priori as 
p<0.05.  Due to the very small number of participants with the outcome, we did not adjust for 
the a priori covariates (age, gender, marital status, housing status, income, education, 
postcode, nicotine dependence, quit attempts, use of cessation aids, partner smoking 
behaviour depression and financial stress) specified for inclusion in the analyses.
10,20
 Part 
way through the study recruitment we discovered a breach in protocol in that some 
participants were informed of their allocated intervention group prior to obtaining consent. 
This problem was rectified after 25 participants had been recruited, and blinding to allocation 
was maintained prior to seeking consent for the remainder of recruitment. However, due to 
the potential for this to introduce some participation bias, the regression model for the 
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primary analysis initially included a variable indicating whether individuals had been 
informed of their intervention status prior to consent. As this variable had no impact on the 
intervention effect, to preserve power it was excluded from the final model. 
For the secondary outcomes a logistic regression model for abstinence outcomes was used 
(validated continuous abstinence at 1 month, self-reported continuous abstinence, CO 
confirmed and self-reported 7-day point prevalence abstinence at one and six months), 
unadjusted for covariates. Linear regression models were used for the number of cigarettes 
smoked per day, and a negative binomial model for number of quit attempts adjusted for 
whether or not participants had been informed of their intervention status prior to consent, 
Heaviness of Smoking Index, depression and anxiety (PHQ4), and self-efficacy, and for 
number of cigarettes, quit method at baseline was included as a covariate due to possible 
imbalance between treatment groups at baseline. Robust standard errors were applied to the 
linear regression to account for slight deviation in the heteroscedasticity of residuals.  
For all outcomes, three types of sensitivity analyses were undertaken to include all 
participants, consistent with the intention-to-treat (ITT) principle: 1) multiple imputation 
(MI)
21,22
 with chained equations to allow for appropriate estimates of variance; 2) analysis 
considering individuals with missing outcome as worst case outcomes (not continuous 
abstainers, no change in number of cigarettes smoked and no quit attempts), consistent with 
common methods of analysis of smoking cessation trials;
16
 and 3) using pattern mixture 
models (PMM),
23
 consistent with a Missing Not at Random mechanism.  
Based on previous pilot studies with similar populations,
24
 we estimated that the control 
group quit rate would be 5%. On the basis that an 8% absolute difference in abstinence would 
be clinically important (i.e., 13% vs 5%), we calculated that a study size of 400 participants 
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(200 per group), allowing for a 30% loss to follow-up, would have 80% chance of detecting 
this difference with a 5% (two-sided) significance level. 
Results 
Figure 1 shows the recruitment and follow-up of participants from 7
th
 February 2012 to 21 
July 2014. Of the 301 excluded, 254 (84.4%) were non-smokers, 17 (5.6%) were under the 
influence of alcohol or other drugs, 8 (2.7%) were too distressed to complete the survey 
(distress related to factors contributing to accessing emergency relief), and 16 (5.3%) had no 
reason recorded and 6 (2.0%) experienced technical issues. Of the 618 eligible individuals, 
300 were randomised to the intervention group, of whom 187 (62%) consented and 318 were 
randomised to the control group, of whom 244 (77%) consented, resulting in 431 participants. 
The control group had a higher completed follow-up rate (return for both 1 and 6 month 
follow-up visits) than the intervention group.  
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Figure 1. CONSORT Flow diagram 
 
Treatment groups were well balanced with respect to baseline characteristics, with the 
possible exceptions of fewer participants in the control group who were separated/divorced 
(Table 1), or last tried to quit smoking by gradually cutting down on cigarettes (Table 2).  
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Table 1. Participant sociodemographic and psychosocial variables at baseline by treatment group (n=431) 
Characteristic Control (n=244) Intervention 
(n=187) 
Total 
 n (%) n (%) n (%) 
Age in years – Mean (SD) 38 (11) 37 (12) 38 (11) 
Gender 
Male 
Female 
 
126 (52) 
118 (48) 
 
95 (51) 
92 (49) 
 
221 (51) 
210 (49) 
Housing 
Own house 
Rental 
Supported/government housing 
Family/friends/motel/street/other 
 
7 (3) 
68 (28) 
119 (49) 
50 (20) 
 
6 (3) 
60 (32) 
87 (47) 
34 (18) 
 
13 (3) 
128 (30) 
206 (48) 
84 (19) 
Aboriginal and/or Torres Strait Islander 48 (20) 26 (14) 74 (17) 
Marital status 
Married/living with partner 
Divorced or separated 
Never married/single 
Widowed 
 
31 (13) 
66 (27) 
140 (57) 
7 (3) 
 
22 (12) 
67 (36) 
95 (51) 
3 (2) 
 
53 (12) 
133 (31) 
235 (55) 
10 (2) 
Education completed 
Completed up to primary school (grade 6) 
Completed secondary school (grade 10-12) 
Tertiary qualifications 
 
43 (18) 
136 (56) 
65 (27) 
 
39 (21) 
101 (54) 
47 (25) 
 
82 (19) 
237 (55) 
112 (26) 
Income amount* 
Less than $200 per week 
$201-$400 per week 
More than $400 per week 
 
68 (30) 
130 (57) 
31 (14) 
 
47 (27) 
104 (59) 
24 (14) 
 
115 (28) 
234 (58) 
55 (14) 
Income source 
Paid employment (full or part time) 
Government benefit 
Other 
 
8 (3) 
230 (94) 
6 (3) 
 
6 (3) 
176 (94) 
5 (3) 
 
14 (3) 
406 (94) 
11 (3) 
Contact with family 
Never/no family 
1-3 days per month/< once a month 
1-2 days per week 
3-4 days per week or more 
 
36 (15) 
72 (30) 
49 (20) 
87 (36) 
 
32 (17) 
46 (25) 
41 (22) 
68 (36) 
 
68 (16) 
118 (27) 
90 (21) 
155 (36) 
Family you can rely on 
No family can rely on 
1-2 family members 
3 or more 
 
69 (28) 
136 (56) 
39 (16) 
 
62 (33) 
92 (49) 
33 (18) 
 
131 (30) 
228 (53) 
72 (17) 
Alcohol use 
Risky consumption 
Non-risky/safe consumption 
No consumption 
 
136 (56) 
41 (17) 
64 (27) 
 
116 (63) 
24 (13) 
44 (24) 
 
252 (59) 
65 (15) 
108 (25) 
Financial stress – mean (SD) 5.7 (1.7) 5.7 (1.8) 5.7 (1.7) 
Depression – median (Q1, Q3) 13 (7, 19) 10 (7, 18) 12 (7, 18) 
Anxiety – median (Q1, Q3) 4 (2, 6) 2 (2, 5) 3 (2, 5) 
Resilience – mean (SD) 2.8 (0.8) 2.8 (0.8) 2.8 (0.8) 
Allocation revealed at recruitment 18 (7%) 7 (4%) 25 (6%) 
* All currency in AUD 
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Table 2. Participant smoking-related variables at baseline by treatment group (n=431) 
Characteristic Control (n=244) Intervention 
(n=187) 
Total 
 n (%) n (%) n (%) 
Cigarettes smoked per day  - median (Q1, Q3) 15 (10, 20) 15 (10, 20) 15 (10, 20) 
Heaviness of Smoking Index 
Low 
Moderate 
High 
 
76 (35) 
103 (48) 
37 (17) 
 
54 (32) 
91 (54) 
23 (14) 
 
130 (34) 
194 (51) 
60 (16) 
Enjoyment of smoking 
Very much 
Quite a bit 
Not particularly 
Not at all 
Don’t know 
 
29 (12) 
80 (33) 
81 (33) 
30 (12) 
24 (10) 
 
29 (16) 
58 (31) 
60 (32) 
24 (13) 
16 (9) 
 
58 (13) 
138 (32) 
141 (33) 
54 (13) 
40 (9) 
Smoker identity 
Happy about being a smoker 
Unhappy about being a smoker 
Hate being a smoker 
Don’t know 
 
15 (6) 
95 (39) 
85 (35) 
49 (20) 
 
11 (6) 
81 (43) 
64 (34) 
31 (17) 
 
26 (6) 
176 (41) 
149 (35) 
80 (19) 
Intention to stop smoking 
Quit in the next 30 days 
Quit in the next 6 months 
Quit but not in next 6 months 
Never quit 
Don’t know 
 
50 (20) 
58 (24) 
42 (17) 
11 (5) 
83 (34) 
 
33 (18) 
63 (34) 
18 (10) 
3 (2) 
70 (37) 
 
83 (19) 
121 (28) 
60 (14) 
14 (3) 
153 (35) 
Motivation to quit 
High 
Moderate 
Low 
 
85 (35) 
101 (42) 
57 (23) 
 
77 (42) 
80 (43) 
28 (15) 
 
162 (38) 
181 (42) 
85 (20) 
Ever made serious quit attempt/ Yes 203 (83) 159 (85) 362 (84) 
Number of serious quit attempts in previous 12 months 
0-1 
2 or more 
 
 
139 (57) 
104 (43) 
 
 
109 (58) 
78 (42) 
 
 
248 (58) 
182 (42) 
Method at last quit attempt 
Stopped smoking abruptly 
Gradual reduction 
Can’t remember 
 
84 (41) 
100 (49) 
19 (9) 
 
50 (31) 
97 (61) 
12 (8) 
 
134 (37) 
197 (54) 
31 (9) 
Quitting self-efficacy 
Extremely sure 
Very sure 
Moderately sure 
Slightly sure 
Not at all 
 
26 (11) 
26 (11) 
67 (27) 
47 (19) 
78 (32) 
 
18 (10) 
26 (14) 
43 (23) 
40 (21) 
60 (32) 
 
44 (10) 
52 (12) 
110 (26) 
87 (20) 
138 (32) 
Friends or family who smoke 
Most or all 
About half 
Less than half/some 
None 
 
96 (39) 
61 (25) 
69 (28) 
18 (7) 
 
74 (40) 
43 (23) 
53 (28) 
17 (9) 
 
170 (39) 
104 (24) 
122 (28) 
35 (8) 
 
Figure 2 shows no statistically significant difference between intervention groups in the 
primary outcome of verified continuous abstinence at six months follow-up (1.4% and 1.0% 
for intervention and control groups; OR 0.77, 95% CI 0.07-8.53, p=0.828).  
There were also no statistically significant differences between groups in the secondary 
outcomes at six months of self-reported continuous abstinence, verified 7-day point 
prevalence abstinence, and self-reported 7-day point prevalence abstinence. Participants in 
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the intervention group reported a significantly lower adjusted mean number of cigarettes 
smoked per day than those in the control group (7.8, 95% CI 4.7-10.8 versus 12.7, 95% CI 
9.8-15.6, p<0.001), and a higher adjusted mean number of quit attempts at six months (3.6, 
95%CI 2.2-5.9 versus 1.6, 95% CI 1-2.3, p < 0.001).  
There was no statistically significant difference between intervention groups in any of the one 
month abstinence outcomes. At one month follow-up the intervention group showed 
significantly fewer adjusted mean number of cigarettes smoked per day than control group 
(10.36, 95%CI 7.68-12.910.8 versus 14.68, 95%CI 12.37-17, p<0.001). 
 
 
Figure 2. Forest plot of primary and secondary outcomes at 1 month (n=326) and 6 months (249) follow-
up. ORs greater than 1 signal that the outcome was favourable for the intervention group. 
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Overall 326 (76%) participants had a one month follow-up and 249 (58%) had a six month 
follow-up. Lack of follow-up was predominantly monotone with 5.6% returning for six 
month follow-up not having attended one month follow-up. Age was associated with being 
missing only in the intervention group (younger in missing: mean 34 years, SD 10 than 
present: mean 41 years, SD 12; p < 0.001) and income was associated with being missing 
only in the control group (lower income in missing than present, p=0.035).  
Sensitivity analyses (MI, worst case and PMM) showed similar results to the available case 
analysis for the majority of outcomes indicating the results were robust to the treatment of 
missing data. Estimates of the intervention effect for number of cigarettes smoked per day at 
6 months varied between analysis approaches: under worst case the effect had diminished but 
was still significant (a difference of 2 cigarettes per day, p=0.02; and for MI we estimated a 
non-significant difference of 3 cigarettes per day (p=0.12). Pattern mixture modelling 
estimated a nullified treatment effect occurred if the missing participants were smoking at 
least 16 cigarettes a day more than those without missing data (an unlikely scenario).  
Intervention adherence: Of those randomised to the intervention group (n=187), 43 (23%) 
did not attend any counselling sessions. Of those who did attend, 22 (15%) attended one 
session, 30 (21%) attended two sessions, 22 (15%) attended three sessions, 25 (17%) attended 
four sessions and 45 (31%) attended all five sessions. Based on the audio-recording of 67 
counselling sessions, the face-to-face sessions (sessions 1-3) averaged 18.09 minutes in 
length (range = 7.16 – 46.44 minutes) and the average length of phone sessions (sessions 4-5) 
was 5.88 minutes (range = 1.53 – 14.53 minutes). In total, 128 intervention group participants 
accepted an offer of NRT. Analysis of 67 counselling session audio-recordings show that, on 
average, fidelity to the treatment manual varied from 46% in the initial sessions, 31% in 
second face to face sessions and 39% in telephone follow ups.   
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Discussion 
Principal findings 
A smoking cessation intervention incorporating behavioural counselling with the option of 
NRT delivered to highly disadvantaged smokers through a community social service by 
trained case-workers resulted in no higher abstinence rates than no intervention. Abstinence 
rates at six months follow-up were low for both groups. Participants in the intervention group 
reported more quit attempts and fewer cigarettes smoked at both one and six month follow-
up. 
This trial is similar to previous trials with homogeneous groups of disadvantaged smokers 
(such as people with a mental illness, Indigenous Australians and prisoners) which have 
found low cessation rates and null outcomes for the behavioural and pharmacotherapy 
interventions.
4,5
 The body of evidence emerging implies that these smokers find it difficult to 
quit, even when provided with current best practice smoking cessation aids.
4,5
 The current 
intervention was evidence based with brief advice, behavioural counselling and BCTs, offer 
of combination NRT, social support and follow-up. One obvious explanation for the lack of 
effect may be low adherence to the intervention. The process measures collected suggest that 
only about a third of smokers attended all five counselling sessions and almost a quarter did 
not attend any at all. Not all participants in the intervention group took up the offer of free 
NRT (128 of 187), and of those who did take up the offer, many did not persist with the full 
recommended course. The outcomes suggest that more effort at increasing adherence to 
treatment is required. Contingency management, with even small financial and non-financial 
rewards for attendance to counselling sessions and adherence to treatment, is an approach 
with evidence of effectiveness with samples of people who use substances.
25
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Another explanation for the negative outcome is that, while the intervention may represent 
best practice for the general population of smokers, it may be insufficient to address the 
complex needs of smokers from highly disadvantaged groups experiencing comorbidities. 
There are a number of modifications that could be made to the intervention to strengthen it. 
Firstly, the provision of brief advice and motivational interviewing across five counselling 
sessions by minimally trained volunteers appears not to be effective for this group of 
smokers. Other research since this trial has shown that smokers receiving support in specialist 
stop smoking centres tend to have a higher short-term quit rate, compared with those 
receiving support in other settings from professionals for whom smoking cessation is only a 
part of their work.
26
 The current sample reported high scores for anxiety, depression, health-
risk alcohol use and financial stress. Referring disadvantaged smokers to more qualified 
counsellors with experience in managing comorbidities is likely to strengthen the behavioural 
component of the intervention.  
Secondly, it is likely that the intervention would be substantially strengthened through the use 
of best-practice NRT, with or without other forms of pharmacotherapy for smoking cessation. 
For example, Cochrane reviews have shown that varenicline and bupropion result in higher 
cessation rates than NRT alone
27
 and are safe for people with mental illness.
28
 Furthermore, 
there are recent suggestions that for smokers who can’t quit or who don’t want to quit, the 
harm of tobacco can be substantially reduced by switching to alternative vaporised forms of 
nicotine delivery.
29
 This is an area that deserves more attention for heavy smokers in 
disadvantaged groups who have tried quitting using other cessation treatments and have 
failed.  
Finally, lack of secure housing, employment, and high prevalence of Indigenous status were 
also characteristics of the sample. Smoking behaviours are part of the social, cultural and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
  Page 20 
 
economic context and environment for smokers from disadvantaged groups.
30
 Investment in 
improving the material and social capital of groups in our society who are disadvantaged is 
likely to lead to improvement in health behaviours such as smoking. The CSSO setting that 
this trial used is an ideal vehicle for approaching this issue, however greater investment by 
government in providing other forms of support to these smokers is likely to improve their 
chances in quitting smoking and leading healthier lives.  
 
This trial recruited all smokers regardless of motivation level. The study found a significant 
increase in quit attempts due to the intervention. Furthermore, the intervention resulted in 
fewer cigarettes smoked over the six-month follow-up period, again implying that the 
intervention encouraged some action, which was insufficient in itself to achieve longer term 
cessation. Testing interventions that are applied for longer and with prolonged use of 
pharmacotherapy support is warranted.  
Strengths and weaknesses 
The most significant limitations relate to participant consent and attrition.  While 49% of 
participants were randomly allocated to the intervention group (n=300) and 51% to the 
control group (n=318), a higher proportion consented in the control group (n=244; 77%) than 
the intervention group (n=187; 62%).  The recruitment procedure involved assessing 
individuals’ smoking status during the health survey was completed on a touchscreen laptop 
computer; all individuals who reported being current smokers were randomised by the 
software to either intervention group or control group and consent for participation in the 
study was then sought. The study protocol specified that consent was sought by the research 
assistant prior to checking the allocation of the individual. However, due to a breach in 
protocol, the first 25 participants were made aware of their allocation prior to consent-
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
  Page 21 
 
gaining, resulting in greater consent into the control group. Similarly, knowledge they would 
be required to return to the centre for three face-to-face counselling sessions if randomised to 
the intervention group may have been a disincentive for some. For the remainder of the 
recruitment, the research assistant and participants were blinded to allocation prior to 
obtaining consent. The impact of the lack of blinding of allocation for the initial participants 
had some impact on the group numbers, which was exacerbated by more participants in the 
intervention group withdrawing consent following allocation to group. The possible bias is 
likely to be small as baseline characteristics were similar between the two intervention 
groups. The attrition rates were high but not unusual for studies of this type
11
 and were 
reasonably similar for the two intervention groups, 47% in the intervention group and 41% in 
the control group at 6 month follow-up. The imbalance in numbers highlights the difficulties 
in recruiting smokers in disadvantaged groups into smoking cessation trials. Evidence-based 
strategies were employed to boost retention, and attrition may have been greater had these 
strategies not been used. The consistency in the results from primary and sensitivity analysis 
to account for missing data points provide confidence that the impact of attrition is minimal. 
Also, the generalisability of the study is limited to similar CSSOs within high-income 
countries and their clients. 
The study has a number of strengths. This trial is one of the first to include a large and 
diverse sample of highly disadvantaged smokers, recruiting 431 participants, regardless of 
motivation to quit. Abstinence was verified using carbon monoxide readings. Self-reported 
abstinence rates were higher than confirmed abstinence, particularly in the intervention group 
highlighting the importance of objective verification of abstinence self-report. Our sensitivity 
analysis used multiple imputation as described in the methods in addition to traditional 
approaches to missing data in smoking cessation studies because evidence shows that the 
assumptions underpinning multiple imputation are more defensible than are those assumed 
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when using other approaches to missing data. The results of the sensitivity analyses were 
consistent with the primary analyses indicating robustness of these analyses. 
Implications from this research 
New smoking cessation interventions for smokers from socially disadvantaged groups need 
to be developed and tested.  The current study was conducted in the context of a high-income 
country with strong tobacco control measures and low general population smoking 
prevalence rate. Smokers who are highly socially disadvantaged appear to require more 
intensive smoking cessation interventions and possibly longer term, than smokers from the 
general population or more affluent groups. This has implications for resourcing and 
timeframes. Referral to specialist services or additional training for counsellors and care 
providers may be appropriate. Furthermore, new stop smoking medicines have become more 
readily available since this trial, including varenicline which has strong evidence of 
effectiveness and should be offered to smokers from disadvantaged groups. 
Conclusions 
In this study, evidence that a case-worker delivered smoking cessation intervention was 
effective at aiding abstinence was lacking.  The secondary outcomes suggest that the 
intervention influenced processes towards abstinence such as increasing the number of 
attempts to quit and reducing the number of cigarettes smoked daily. For this population of 
highly disadvantaged smokers, with comorbidities, high proportion of Indigenous Australians 
and financial concerns, these are important outcomes. Because of the exceptionally high 
smoking rates amongst socially disadvantaged groups worldwide it is imperative that 
research continues to examine strategies for promoting smoking cessation.  
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